NCT00448214

Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation

Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation - A Double Blind, Parallel, Dose-finding Study in Comparison With Open Label Warfarin

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 448 (actual)
• Sponsor: Astellas Pharma Inc · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the safety and tolerability of YM150 in subjects with non-valvular atrial fibrillation (NVAF)and to obtain information on pharmacokinetics and pharmacodynamics (anti-thrombotic potential) in the target population

Conditions

• Atrial Fibrillation

Interventions

Type	Name	Description
DRUG	YM150	Oral
DRUG	warfarin	Oral

Timeline

• Start date: 2007-03-01
• Primary completion: 2008-10-01
• Completion: 2008-10-01
• First posted: 2007-03-16
• Last updated: 2011-12-19

Locations

18 sites across 10 countries: Australia, Hong Kong, Japan, Malaysia, New Zealand, Singapore, South Africa, South Korea, Taiwan, Thailand